you know what I may have just had a mental fart there. you're right!
Thats much more in line with the previous period's margin profile, still a drop in EBIT margin but not so severe. Im still curious as to why that is, given what must have been a massive increase in sales. Maybe it is simply just a big increase in formulation costs, which bodes very well for the future, and maybe a slight decrease in gross margins (although incremental gross margins should be much higher than average).
Something is a bit off though, as @vestro previously thought they might have done as much as 1.5m NPAT in the first five weeks based on his understanding of pricing and incremental input costs, yet we ended up with 1.8m NPAT for the whole quarter.
